What Is The “Safest” Non-Steroidal Anti-Inflammatory Drugs?

P. Ungprasert, W. Kittanamongkolchai, Chrystal D. Price, Supawat Ratanapo, Napat Leeaphorn, Daych Chongnarungsin, W. Cheungpasitporn
{"title":"What Is The “Safest” Non-Steroidal Anti-Inflammatory Drugs?","authors":"P. Ungprasert, W. Kittanamongkolchai, Chrystal D. Price, Supawat Ratanapo, Napat Leeaphorn, Daych Chongnarungsin, W. Cheungpasitporn","doi":"10.3844/AMJSP.2012.115.123","DOIUrl":null,"url":null,"abstract":"Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) which are widely used in clinical practice are also very well-known for their various adverse reactions. Each NSAID has its own unique safety profile and selecting an appropriate NSAID m ust be individualized for each patient based on his or her medical needs and risk factors. We reviewed literatures on NSAIDs, focusing on their adverse reaction profile. We reviewed and compared the inci dence of adverse reaction from individual NSAIDs according to organ systems. This review includes both selective COX-2 inhibitors and non- selective NSAIDs. Based on the most up-to-date evidence, ibuprofen appears to be the preferred NSAIDs based on its favorable GI and nephrotoxicity profiles. Naproxen might be considered in patients who have greater cardiac risk. Celecoxib, at the do se of less than or equal to 200 mg day -1 , might be an option in the patients who are at high risk for GI bleeding. Key word: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), COX-2 inhibitor, adverse drug reaction, adverse reactions, safety profile, clinic al practice, organ systems","PeriodicalId":89887,"journal":{"name":"American medical journal","volume":"3 1","pages":"115-123"},"PeriodicalIF":0.0000,"publicationDate":"2012-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3844/AMJSP.2012.115.123","citationCount":"29","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3844/AMJSP.2012.115.123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 29

Abstract

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) which are widely used in clinical practice are also very well-known for their various adverse reactions. Each NSAID has its own unique safety profile and selecting an appropriate NSAID m ust be individualized for each patient based on his or her medical needs and risk factors. We reviewed literatures on NSAIDs, focusing on their adverse reaction profile. We reviewed and compared the inci dence of adverse reaction from individual NSAIDs according to organ systems. This review includes both selective COX-2 inhibitors and non- selective NSAIDs. Based on the most up-to-date evidence, ibuprofen appears to be the preferred NSAIDs based on its favorable GI and nephrotoxicity profiles. Naproxen might be considered in patients who have greater cardiac risk. Celecoxib, at the do se of less than or equal to 200 mg day -1 , might be an option in the patients who are at high risk for GI bleeding. Key word: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), COX-2 inhibitor, adverse drug reaction, adverse reactions, safety profile, clinic al practice, organ systems
什么是“最安全”的非甾体抗炎药?
非甾体类抗炎药(NSAIDs)广泛应用于临床,但其不良反应也非常多。每一种非甾体抗炎药都有其独特的安全性,选择合适的非甾体抗炎药必须根据每位患者的医疗需求和风险因素进行个体化。我们回顾了有关非甾体抗炎药的文献,重点介绍了它们的不良反应概况。我们回顾并比较了不同器官系统的非甾体抗炎药的不良反应发生率。本文综述了选择性COX-2抑制剂和非选择性非甾体抗炎药。根据最新的证据,布洛芬似乎是首选的非甾体抗炎药,因为它具有良好的胃肠道和肾毒性。对于心脏风险较大的患者,可以考虑使用萘普生。塞来昔布在小于或等于200mg day -1的剂量下,可能是胃肠道出血高风险患者的一种选择。关键词:非甾体抗炎药,COX-2抑制剂,药物不良反应,不良反应,安全性,临床实践,器官系统
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书